SEARCH · PubMed Health
Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Bacterial endocarditis was diagnosed in a 4-year-old male German shorthaired Pointer with a 4-month history of shifting lameness and intermittent fever. The dog died in spite of treatment for progressive depression and dehydration. Blood cultures were positive for Erysipelothrix rhusiopathiae strain 7, which is known to be pathogenic for dogs. The clinical diagnosis was confirmed at necropsy.20
A case of erysipeloid with bacteraemia caused by Erysipelothrix rhusiopathiae (ER) in a previously healthy 41-year old man is presented. The bacterium was probably introduced by the bite of a dog. He was treated successfully with penicillin V. The ER bacteraemia occurred without complications of endocarditis.
Among a group of 16 argentine strains of Erysipelothrix rhusiopathiae 2 new serotypes have been found. Typing was performed by means of the agar gel diffusion test. Extracts produced by autoclaving the organisms for 1 hour at 120 degrees C were used as antigen. Antisera against all known types were produced in rabbits. Extracts produced from the two strains in question (Baño 36 and Baño 107) did not react with any of the knwon type antisera. Antisera against the two strains did not react with extracts of any of the known type strains, but only with extract of their homologous strains. The two new types were designated Type 21 (Baño 36) and Type 22 (Baño 107).
Erysipelothrix rhusiopathiae is becoming more commonly recognized in humans and has the potential for significant morbidity and mortality. In this article, we describe one patient's clinical symptoms after occupational exposure to E rhusiopathiae and its sequela. We discuss the natural history of the organism, three major categories of human disease, and treatment options.
The proteins of 12 Erysipelothrix rhusiopathiae strains were radiolabelled with L-[35S] methionine, and the protein fractions were detected by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and autoradiography. The strains were found to differ from each other in their protein patterns; thus, it was concluded that the method applied could provide useful data for the identification of strains. The described procedure was used for determining the percentage contents of protein fractions of identical molecular mass within the strains compared. The results show that there is no significant correlation between the type of the strains and the percentage of identical molecular weight fractions.
Studies into the nutrient demand of Erysipelothrix insidiosa led to the preparation of a nutritive medium with high bacterial yield which is recommended for quantity breeding of bacteria. The medium was complex and did not contain serum but the following components: peptone S, yeast extract, glucose, Na2HPO4, arginine, and Tween 80.
AIMS: To develop an economical, safe and simple vaccination system against swine erysipelas using SpaA-antigen producing Lactococcus lactis. METHODS AND RESULTS: The spaA gene of Erysipelothrix rhusiopathiae was inserted into a shuttle plasmid pSECE1 to construct pSECE1.3. The SpaA produced in L. lactis maintained a stable antigenicity without degrading in growth. After mice were inoculated intranasally and orally with pSECE1.3-carrying L. lactis cells, IgG and IgA specific to SpaA were detected, and all the mice survived a challenge with 100 LD(50) of E. rhusiopathiae Tama-96 in the inner thigh. CONCLUSIONS: SpaA-producing L. lactis appears useful as an effective subunit vaccine against swine erysipelas. SIGNIFICANCE AND IMPACT OF THE STUDY: In this vaccination system, purification of the antigen and injection are unnecessary, leading to a reduced production cost, reduced labour and less stress to the animals. This vaccination system of the lactic acid bacteria should be a safe and suitable vehicle for a polyvalent vaccine.
The mouse-protective activity of Erysipelothrix rhusiopathiae culture supernatant fluids exists in a polydisperse form, ranging in density from aggregates which sediment at 10,000 x g for 3 hr to soluble units which will not sediment at 198,000 x g for 12 hr. A partially purified protective antigen has been isolated from the aggregates sedimented from a concentrate of the culture supernatant fluid at 20,000 x g for 3 hr. These aggregates contained the major protective antigen or antigens of E. rhusiopathiae, since, in addition to inducing active immunity, they adsorbed essentially all of the passively protecting antibody from rabbit antiserum produced by immunization with whole culture. The protective activity in these aggregates was destroyed by trypsin and greatly diminished by muramidase and heating at 64 C, but was not affected by lipase or ribonuclease.
A particulate fraction of Erysipelothrix rhusiopathiae cultures has been subjected to butanol extraction and treatment with surface-active agents in an attempt to solubilize a protective antigen. The particulate fraction was partitioned into the butanol layer but was not solubilized. Only sodium dodecyl sulfate solubilized the particles. The soluble protective activity was not sedimented by centrifugation at 198,000 x g for 12 hr but was excluded by Sephadex G-200. Immunodiffusion studies of the soluble fraction demonstrated eight antigens, five of horse serum origin and three of E. rhusiopathiae origin. Ultracentrifugation indicated that spontaneous reaggregation occurred after removal of the sodium dodecyl sulfate. Analytical ultracentrifugation showed that 90% of the sodium dodecyl sulfatetreated material migrated as a single homogeneous 3.5S component. The physical and biological characteristics of the protective activity suggest that the protective antigen is a glyco-lipoprotein.
A cell-free crude extract of Erysipelothrix rhusiopathiae injected intravenously in rabbits induced pathological lesions of the synovial tissue similar to the lesions seen in rheumatoid arthritis. Fluorescence techniques utilizing tagged specific antiserum and fluorescent-tagged antigen injected into nonsensitized rabbits demonstrated the localization of antigen exclusively in the synovium. Localized concentration of fluorescence was demonstrated as early as 1 hr after injection, before histological changes were apparent. After 48 hr, the fluorescence was concentrated in focal areas and early pathological changes characterized as "mesenchymal activation" were observed. A consideration of the significant role of exogenous antigen in the sensitivity arthritides is discussed.
Chronic polyarthritis was induced in pigs by injection of Erysipelothrix rhusiopathiae and the in vivo activation of chondrocytes by cytokines was then investigated in the affected joints by immunocytochemistry. A polyclonal antiserum which recognises surface markers on in vitro interleukin 1 activated porcine chondrocytes was used to detect activated chondrocytes in all zones of the cartilage from diseased joints. In contrast, cartilage removed from an unaffected joint in the same animal showed no chondrocyte activation. Inflammatory synovial tissue removed from diseased joints and cocultured with cartilage from the unaffected joint induced activation of adjacent chondrocytes. The presence of interleukin 1 in the inflammatory cells of the synovium was confirmed and major histocompatibility complex (MHC) class II antigens were detected as a marker of synovial activation. Chondrocytes were found not to express class II antigens in cartilage from either the diseased or the unaffected joint. These observations show that the porcine erysipelas model of arthritis will be useful in facilitating a novel approach to monitoring the behaviour of individual chondrocytes under pathophysiological conditions.
Investigations on extracts from Erysipelothrix (E.) rhusiopathiae carried out within the last few years yielded the identification of a species-specific proteinaceous antigen of 66-64 kDa. The protective properties of this protein presented in particular in crude NaOH and NaOH-EDTA but not in acid and heat extracts could be demonstrated in mice and pigs vaccinated with the electroeluted 66-64 kDa antigen or treated with polyclonal and monoclonal antibodies, respectively. The identification and characterization of the 66-64 kDa protein as a protective antigen of (E.) rhusiopathiae can be regarded as a basis for a possible replacement of the official mouse protection test in vaccine testing by an in vitro assay.
Erysipelothrix rhusiopathiae is widespread among many species of animals including fish. Erysipeloid is the most common infection caused by this bacterium in man; systemic infection, with endocarditis, is rare. Most of the affected patients risk exposure to the organism at work. Two patients with E. rhusiopathiae infections are described; one with erysipeloid after slaughtering a deer, the other with fatal endocarditis after gutting an eel. Erysipeloid may be confused with "seal finger", but this disease probably has a different microbial etiology and requires different antibiotic treatment.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.